DESCRIPTION: To date, no medications have been approved expressly for the treatment of methamphetamine dependence, leaving few options for doctors and patients battling this particular addiction. This clinical trial sought to determine the safety and tolerability of the medication ibudilast in non-treatment seeking, methamphetamine-dependent volunteers.The study took place at the Harbor-UCLA Medical Center in Torrance.

Preliminary outcomes of the trial were presented at the 2013 College of Problems on Drug Dependence Conference in San Diego. Click here to read the press release and stay tuned for additional results.


1.DeYoung, D. Z., Heinzerling, K. G., Swanson, A. N., Tsuang, J., Furst, B. A., Yi, Y., … & Shoptaw, S. J. (2016). Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment. Journal of clinical psychopharmacology. 2016 Aug;36(4):347-54.

2. Li MJ, Briones MS, Heinzerling KG, Kalmin MM, Shoptaw SJ. Ibudilast attenuates peripheral inflammatory effects of methamphetamine in patients with methamphetamine use disorder. Drug Alcohol Depend. 2020 Jan 1;206:107776. Epub 2019 Nov 26. PMID: 31812878; PMCID: PMC7012103.

3. Worley MJ, Swanson A-N, Heinzerling KG, Roche DJ, Shoptaw S. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. Drug Alcohol Depend. 2016 May 1;162:245-50. Epub 2016 Mar 3. Erratum in: Drug Alcohol Depend. 2018 Sep 1;190:120. PMID: 26993372; PMCID: PMC5349508.